2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 625

Control of Hypertension and Hypercholesterolemia Is Not Associated with a Decreased Rate of Atherosclerotic Vascular Events in Patients with Systemic Lupus Erythematosus
Abstract Number: 2180

Coronary Flow Reserve and Asymmetric Dimethylarginine Levels: New Measurements for Identifying Subclinical Atherosclerosis in Patients with Primary Sjögren’s Syndrome
Abstract Number: 1795

Correction for Basophil and Monocyte Frequencies Identifies Specific Gene Expression Differences Associated with SLE Disease Flare: Interim Report From the Bold (Biomarkers of Lupus Disease) Study
Abstract Number: 1969

Correction of Vitamin D Insufficiency with the Fixed Daily Combination Strontium Ranelate 2 g/Vitamin D₃ 1000 IU Over 12 Months
Abstract Number: 545

Correlates of Inflammatory Back Pain in a Nationally Representative Sample of the US Population
Abstract Number: 1509

Correlates of Skin Gene Expression Profile in Systemic Sclerosis
Abstract Number: 2314

Correlation Between Abatacept and Rheumatoid Factor – Can Rheumatoid Factor Be a Predictive Factor for Abatacept?
Abstract Number: 116

Correlation Between Clinical and Ultrasonographic Examination of the Calcaneal Enthesis in Patients with Ankylosing Spondylitis: A Controlled Study
Abstract Number: 2351

Correlation Between Hypoechoic Halo of the Temporal Arteries and Clinical, Laboratory, and Temporal Artery Biopsy Findings in Patients with Giant Cell Arteritis
Abstract Number: 2658

Correlation Between Mefv Genotype and Interleukin (IL)1β secretion and Role of the nlr Family Pyrin Domain Containing 3 (Nlrp3) Inflammasome in Patients with Familial Mediterranean Fever (FMF)
Abstract Number: 2162

Correlation of A Multi-Biomarker Disease Activity (VECTRA™ DA) Score with Clinical Disease Activity and Its Components with Radiographic Progression in Rheumatoid Arthritis Patients Treated with Tofacitinib
Abstract Number: 2159

Correlation of a Multi-Biomarker Disease Activity Response Assessment to Disease Activity Score 28 (C-Reactive Protein) Response Assessment and Omeract Ramris Scores in a Placebo-Controlled Rheumatoid Arthritis Clinical Trial with Abatacept (ASSET)
Abstract Number: 684

Correlation of Signal Transducers and Activators of Transcription-1 and Microrna-146a with Anaemia and Other Clinical Features in Systemic Lupus Erythematosus Patients
Abstract Number: 91

Correlations of Single Item Health Literacy Screening Questions with Established Measures of Health Literacy in Subjects with Rheumatoid Arthritis
Abstract Number: 2349

Corticosterois Therapy Restaured Treg/Th17 Balance in Patients with Polimyalgia Rheumatica

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].